BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tseng TC, Kao JH. Elimination of Hepatitis B: Is It a Mission Possible? BMC Med 2017;15:53. [PMID: 28292309 DOI: 10.1186/s12916-017-0820-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Bhat SA, Kazim SN. HBV cccDNA─A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure. ACS Omega. [DOI: 10.1021/acsomega.2c02216] [Reference Citation Analysis]
2 Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]
3 Tseng TC, Hosaka T, Liu CJ, Suzuki F, Hong CM, Kumada H, Yang WT, Hsu CY, Su TH, Yang HC, Liu CH, Chen PJ, Chen HH, Kao JH. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. Am J Gastroenterol 2022;117:748-57. [PMID: 35191399 DOI: 10.14309/ajg.0000000000001691] [Reference Citation Analysis]
4 Tseng TC, Wu JW, Kao JH. Looking Into the Crystal Ball: A Novel Biomarker for Outcomes of Patients With Chronic Hepatitis B Virus Infection. Hepatol Commun 2022;6:5-7. [PMID: 34957702 DOI: 10.1002/hep4.1856] [Reference Citation Analysis]
5 Yang YC, Yang HC. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021;14:4. [PMID: 35062208 DOI: 10.3390/v14010004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, Yang SS, Su WW, Wu JC, Lee TH, Peng CY, Tseng KC, Qin A, Huang YW, Chen PJ. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open 2021;5:929-40. [PMID: 34386602 DOI: 10.1002/jgh3.12613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Abbas Z, Abbas M. Challenges in Formulation and Implementation of Hepatitis B Elimination Programs. Cureus 2021;13:e14657. [PMID: 33907651 DOI: 10.7759/cureus.14657] [Reference Citation Analysis]
8 Tseng TC. Another oral antiviral treatment, but still far away from hepatitis B virus cure. Clin Mol Hepatol 2021;27:281-2. [PMID: 33687857 DOI: 10.3350/cmh.2021.0072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh HN, Wong C, Wong C, Zhang J, Li J, Kao JH. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int 2021;15:105-13. [PMID: 33547557 DOI: 10.1007/s12072-020-10124-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Jensen JD. Studying Population Genetic Processes in Viruses: From Drug-Resistance Evolution to Patient Infection Dynamics. Encyclopedia of Virology 2021. [DOI: 10.1016/b978-0-12-814515-9.00113-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, Yang HC, Yang WT, Lin CH, Yu ML, Lai HC, Tanaka Y, Nguyen MH, Liu CH, Chen PJ, Chen DS, Kao JH. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. Liver Cancer 2020;9:207-20. [PMID: 32399434 DOI: 10.1159/000504650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
13 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
14 Zhu DD, Zhang XP, Yu HL, Liu RX, Shen CB, Zhang WF, Cui Y, Guo XD. Kinetic stability studies of HBV vaccine in a microneedle patch. International Journal of Pharmaceutics 2019;567:118489. [DOI: 10.1016/j.ijpharm.2019.118489] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Tillmann HL, Samuel G. Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opin Pharmacother 2019;20:873-85. [PMID: 30857443 DOI: 10.1080/14656566.2019.1583744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology 2019;156:384-99. [PMID: 30268787 DOI: 10.1053/j.gastro.2018.07.058] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 18.8] [Reference Citation Analysis]
17 Xie HP, Liu ZP, Zhang JS, Dai M, Xiao GM, Wu WK, Yang HZ. Traditional Chinese Medicine Syndrome Patterns and Their Association with Hepatitis B Surface Antigen Levels during the Natural History of Chronic Hepatitis B Virus Infection. Evid Based Complement Alternat Med 2018;2018:7482593. [PMID: 30369956 DOI: 10.1155/2018/7482593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Kao J. Hepatitis B: From control to cure. Journal of the Formosan Medical Association 2018;117:868-70. [DOI: 10.1016/j.jfma.2018.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
19 Ginzberg D, Wong RJ, Gish R. Global HBV burden: guesstimates and facts. Hepatol Int 2018;12:315-29. [DOI: 10.1007/s12072-018-9884-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
20 Li T, Wu Y, Tsai H, Sun C, Wu Y, Wu H, Pei Y, Lu K, Yen TT, Chang C, Chan H, Tao M, Liou J, Chang MD, Su I, Wang LH. Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis: HBV LHBS attenuates G 2 /M checkpoint and induces cytokinesis failure. J Pathol 2018;245:502-13. [DOI: 10.1002/path.5102] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
21 Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. Aliment Pharmacol Ther 2018;47:1480-9. [PMID: 29601647 DOI: 10.1111/apt.14619] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
22 Lin CL, Kao JH. Prevention of mother-to-child transmission: the key of hepatitis B virus elimination. Hepatol Int 2018;12:94-6. [PMID: 29619622 DOI: 10.1007/s12072-018-9863-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Sackman AM, Pfeifer SP, Kowalik TF, Jensen JD. On the Demographic and Selective Forces Shaping Patterns of Human Cytomegalovirus Variation within Hosts. Pathogens 2018;7:E16. [PMID: 29382090 DOI: 10.3390/pathogens7010016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
24 Su TH, Kao JH. Unmet Needs in Clinical and Basic Hepatitis B Virus Research. J Infect Dis 2017;216:S750-6. [PMID: 29156048 DOI: 10.1093/infdis/jix382] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]